This segment focuses on the research, development, and commercialization of pharmaceutical products for the diagnosis and treatment of allergic diseases. Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is actively involved in developing and manufacturing allergy immunotherapy products, including sublingual immunotherapy (SLIT) using standardized allergen extracts. Research and development efforts include clinical trials to assess the efficacy and safety of these treatments, such as Artemisia annua sublingual immunotherapy. The company utilizes advanced technologies for allergen extraction and formulation. The patient impact is significant, as these treatments aim to alleviate symptoms and improve the quality of life for individuals suffering from allergic rhinitis and other allergic conditions. Market positioning is strong in China, with opportunities for international expansion. Regulatory aspects involve obtaining approvals for new drug formulations and clinical trial protocols. Partnerships and collaborations with healthcare professionals and research institutions are crucial for clinical trials and market access.

This segment encompasses the development, production, and sale of skin care products. While specific details about the research and development activities are limited, the company likely formulates and manufactures products designed to address various skin conditions or provide general skin health benefits. The technologies and methodologies employed may include the use of specific ingredients and formulations to achieve desired outcomes. The therapeutic areas covered include general skin care, with potential applications for conditions such as eczema or other dermatological issues. The patient impact involves improving skin health and appearance. Market positioning is likely within the Chinese market, with potential for expansion. Future opportunities include product diversification and innovation in formulations. Regulatory aspects involve compliance with cosmetic product regulations. Partnerships may include collaborations with dermatologists or skincare specialists.

This segment focuses on the research, development, and potential application of stem cell-related products or therapies. The company's activities may include research into stem cell technologies, such as the use of stem cells for regenerative medicine or other therapeutic applications. The technologies and methodologies used could involve cell culture, cell differentiation, and other advanced biotechnological techniques. The therapeutic areas covered may include regenerative medicine, with potential applications for various diseases or conditions. The patient impact could be significant, offering potential for tissue repair and disease treatment. Market positioning is likely within the Chinese market, with potential for future expansion. Future opportunities include the development of new stem cell-based therapies and products. Regulatory aspects involve compliance with regulations related to stem cell research and clinical trials. Partnerships and collaborations with research institutions and healthcare providers are essential for advancing stem cell-related projects.